ISSN: 2706-8870
Volume 7, Number 2 (2022)
Year Launched: 2016

Simiao Yongan Decoction in Treating Herpes Zoster: A Network Pharmacology- Based study

Volume 7, Issue 2, April 2022     |     PP. 65-85      |     PDF (1120 K)    |     Pub. Date: March 7, 2022
DOI: 10.54647/cm32778    99 Downloads     5160 Views  

Author(s)

Lusheng Huang, Department of Anesthesiology, The First People's hospital of Nanning, China
Shuangshuang Hu, Ultrasonic Department,Guangxi Bone Injury Hospital, China

Abstract
Background Herpes zoster (HZ) is an infectious disease, which impacts on patients' quality of life. Herein, we employed the network pharmacological methods to predict the target of bioactive components in Simiao Yongan Decoction (SYD) in the treatment of HZ.
Method We utilized the TCMSP and GenneCards databases to screen for the bioactive components of SYD, their targets, and HZ related targets. The bioactive component-target network of "SYD" was constructed by Cytoscape. Also, we constructed a PPI (protein-protein interaction) network using the Search Tool for the Retrieval of Interacting Genes Database (STRING) to identify the potential SYD targets for the treatment of HZ. "ClusterProfiler" in R-project was used for Gene Ontology (GO) analysis and KEGG pathway enrichment analysis. The SYD hub genes were screened by component-target network topological parameters, and the findings confirmed by molecular docking.
Results We selected 126 bioactive components and 235 targets. By assessing the topological parameters of degree network, we identified five hub genes related to SYD based therapy against HZ, that is, CDK2, CASP3, JUN, AKT1, and MAPK1. According to the results of enrichment analysis, the treatment of HZ with SYD mainly involved toll-like receptor signaling, C-type lectin receptor, MAPK, PI3K-Akt, and other signal pathways. The results of molecular docking analysis showed that the binding energy between SYD bioactive compounds and hub targets was good.
Conclusion The results showed that SYD is effective in the treatment of HZ through multi-target and multi-pathway. It provides certain theoretical support for SYD treatment of HZ and a new direction for the treatment of HZ by traditional Chinese medicine.

Keywords
Herpes zoster, Simiao Yongan Decoction, Network pharmacological, Molecular docking

Cite this paper
Lusheng Huang, Shuangshuang Hu, Simiao Yongan Decoction in Treating Herpes Zoster: A Network Pharmacology- Based study , SCIREA Journal of Clinical Medicine. Volume 7, Issue 2, April 2022 | PP. 65-85. 10.54647/cm32778

References

[ 1 ] Bajwa ZH, Ho CC. Herpetic neuralgia. Use of combination therapy for pain relief in acute and chronic herpes zoster. Geriatrics. 2001;56(12):18-24.
[ 2 ] Donahue JG, Choo PW, Manson JE, et al.The incidence of herpes zoster[J].Arch Intern Med, 1995, 155 :1605-1609
[ 3 ] Nikkels, A.F. and G.E. Piérard, Oral Antivirals Revisited in the Treatment of Herpes Zoster. 2002. 3(9): p. 591-598.
[ 4 ] ACYCLOVIR MIGHT PRODUCE NEUROLOGICAL SIDE EFFECTS. Inpharma Wkly. 395, 5 (1983).
[ 5 ] Shi qiaoyin.Modified Simiao Yongan Decoction for 127 Cases of Herpes Zoster[J].Guangming Journal of Chinese Medicine,2006(09):84-85.
[ 6 ] Guoqin Chen,et al.Clinical Observation of 36 Cases of Postherpetic Neuralgia Treated with Modified Simiao Yongan Decoction[J].Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine,2010,9(03):176-177.
[ 7 ] Hopkins AL (2007) Network pharmacology. Nat Biotechnol 25(10):1110
[ 8 ] Jinlong Ru; Peng Li; Jinan Wang; Wei Zhou; Bohui Li; Chao Huang; Pidong Li; Zihu Guo; Weiyang Tao; Yinfeng Yang; Xue Xu; Yan Li; Yonghua Wang; Ling Yang. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminformatics. 2014 Apr 16;6(1):13.
[ 9 ] Xu X, Zhang W, Huang C, Li Y, Yu H, Wang Y, Duan J, Ling Y (2012) A novel chemometric method for the prediction of human oral bioavailability. Int J Mol Sci 13(6):6964–6982.
[ 10 ] Stelzer G, Rosen R, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Iny Stein T, Nudel R, Lieder I, Mazor Y, Kaplan S, Dahary D, Warshawsky D, Guan - Golan Y, Kohn A, Rappaport N, Safran M, and Lancet D. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis , Current Protocols in Bioinformatics(2016), 54:1.30.1 - 1.30.33.
[ 11 ] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, von Mering C.STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.Nucleic Acids Res. 2019 Jan; 47:D607-613.
[ 12 ] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks Genome Research 2003 Nov; 13(11):2498-504
[ 13 ] Ashburner et al. Gene ontology: tool for the unification of biology. Nat Genet. May 2000;25(1):25-9.
[ 14 ] Kanehisa, M.; "Post-genome Informatics", Oxford University Press (2000).
[ 15 ] O. Trott, A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading, Journal of Computational Chemistry 31 (2010) 455-461
[ 16 ] K. Kawabata, R. Mukai, A. Ishisaka Quercetin and related polyphenols: new insights and implications for their bioactivity and bioavailability Food Funct, 6 (2015), pp. 1399-1417
[ 17 ] H. Yang, T. Yang, C. Heng, Y. Zhou, Z. Jiang, X. Qian, L. Du, S. Mao, X. Yin, Q. Lu Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice Phytother Res., 33 (2019), pp. 3140-3152
[ 18 ] D.A. Valerio, S.R. Georgetti, D.A. Magro, R. Casagrande, T.M. Cunha, F.T. Vicentini, S.M. Vieira, M.J. Fonseca, S.H. Ferreira, F.Q. Cunha, W.A. Verri Jr.Quercetin reduces inflammatory pain: inhibition of oxidative stress and cytokine production J. Nat. Prod., 72 (2009), pp. 1975-1979
[ 19 ] Y.W. Liu, X.L. Liu, L. Kong, M.Y. Zhang, Y.J. Chen, X. Zhu, Y.C. Hao Neuroprotection of quercetin on central neurons against chronic high glucose through enhancement of Nrf2/ARE/glyoxalase-1 pathway mediated by phosphorylation regulation Biomed. Pharmacother., 109 (2019), pp. 2145-2154
[ 20 ] Z.H. Yao, X.L. Yao, Y. Zhang, S.F. Zhang, J.C. Hu Luteolin could improve cognitive dysfunction by inhibiting neuroinflammation Neurochem Res, 43 (2018), pp. 806-820
[ 21 ] C. Nunes, L. Almeida, R.M. Barbosa, J. Laranjinha Luteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation Food Funct, 8 (2017), pp. 387-396
[ 22 ] P. Lin, X.H. Tian, Y.S. Yi, W.S. Jiang, Y.J. Zhou, W.J. Cheng Luteolin-induced protection of H(2)O(2)-induced apoptosis in PC12 cells and the associated pathway Mol Med Rep, 12 (2015), pp. 7699-7704
[ 23 ] A. Mobasheri Intersection of inflammation and herbal medicine in the treatment of osteoarthritis Curr Rheumatol Rep, 14 (2012), pp. 604-616
[ 24 ] H.-H. Park, S. Lee, H.-Y. Son, S.-B. Park, M.-S. Kim, E.-J. Choi, et al.Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells Arch Pharm Res, 31 (2008), p. 1303
[ 25 ] Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: Quarrel and harmony among siblings. J. Cell Sci. 2004;117:5965–5973. doi: 10.1242/jcs.01589.
[ 26 ] Eltzschig Holger K, Eckle Tobias. Ischemia and reperfusion--from mechanism to translation.[J]. Nature Medicine, 2011, 17(11):1391-401.
[ 27 ] Anne Sandrine L, Govek Eve-Ellen, Ayrault Olivier, et al. WNT3 inhibits cerebellar granule neuron progenitor proliferation and medulloblastoma formation via MAPK activation.[J]. PLoS ONE, 2013, 8(11):e81769.
[ 28 ] Barton GM, Medzhitov R (2003) Toll-like receptor signaling pathways. Science 300: 1524–1525. doi: 10.1126/science.1085536.
[ 29 ] Che, Guanglu et al. ?Knockdown of Heparanase Suppresses Invasion of Human Trophoblasts by Activating p38 MAPK Signaling Pathway.??Disease markers?vol. 2018 7413027. 17 Apr. 2018, doi:10.1155/2018/7413027.
[ 30 ] Brunet A , Datta S R , Greenberg M E . Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway[J]. Current Opinion in Neurobiology, 2001, 11(3):297-305.